CORCEPT THERAPEUTICS INCORPORATED

NASDAQ: CORT (Corcept Therapeutics Incorporat)

Last update: 18 hours ago

63.62

-1.36 (-2.09%)

Previous Close 64.98
Volume 1,091,156
Avg. Volume (3M) 1,257,842
Market Cap 6,955,109,888
Price / Earnings (TTM) 47.78
Price / Earnings (Forward) 13.21
Price / Sales 8.41
Price / Book 8.89
52 Weeks Range
28.66 (-54%) — 126.38 (98%)
Earnings Date 3 Nov 2026
Profit Margin 16.84%
Operating Margin (TTM) 11.51%
Diluted EPS (TTM) 1.33
Quarterly Revenue Growth (YOY) 64.00%
Quarterly Earnings Growth (YOY) 544.60%
Total Debt/Equity (MRQ) 1.08%
Current Ratio (MRQ) 3.01
Operating Cash Flow (TTM) 198.11 M
Levered Free Cash Flow (TTM) 132.18 M
Return on Assets (TTM) 7.46%
Return on Equity (TTM) 22.15%

AIStockmoo Score

-1.5
Priced high for its earnings growth. info
Dearer than its usual valuation. info
Earns well above its cost of capital. Returns on capital falling. info
Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Holdings' Sentiment info NA
No clear net insider buying or selling. info
Institutions net -1.23% of shares in their latest 13F filings: 303 holders increased, 202 decreased (quarter to 30 Sep 2026). info
Short interest -2.9% from 31 Aug to 30 Oct 2026, 8.1 days to cover (FINRA). info
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
The price implies earnings growth of 27.1% a year; the business can fund about 15.0% a year. info
Earnings per share have gone up and down. info
Below its medium-term trend line. info
Price is near its 52-week average. Up over 5 years. info
Short-term momentum falling. info
Price is between support and resistance. Levels trending down. info
Final Score -1.48
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Corcept Therapeutics Incorporat Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
CORT 7 B - 47.78 8.89 -1.5
SYRE 9 B - - 10.08 1.1
MDGL 9 B - - 14.74 -0.4
DFTX 5 B - - 4.54 0.0
FOLD 5 B - - - 0.0
TARS 4 B - - 36.00 0.6

Select this tab to load the latest available analysis.

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 11.32%
% Held by Institutions 74.47%

Ownership

Name Date Shares Held
Parallel Advisors, Llc 30 Sep 2026 3,902,544
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
SWISHER DANIEL N JR - 73.35 -1,500 -110,025
Aggregate Net Quantity -1,500
Aggregate Net Value ($) -110,025
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 73.35
Name Holder Date Type Quantity Price Value ($)
SWISHER DANIEL N JR Director 10 Nov 2026 Automatic sell (-) 1,500 73.35 110,025
SWISHER DANIEL N JR Director 10 Nov 2026 Option execute 1,500 - -

Institutions

Institutional ownership: 82.72%

Positions Holders Shares
Increased 303 8,099,224
Decreased 202 9,944,764
New 130 1,880,719
Sold out 40 1,378,493

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 9,125,717 8.1
15 Oct 2026 8,588,418 12.3
30 Sep 2026 8,540,393 3.6
15 Sep 2026 9,350,914 9.9
31 Aug 2026 9,399,154 11.9
14 Aug 2026 9,696,757 10.5

FINRA short interest via Nasdaq, reported twice a month.

6 Positive 2 Negative 7 Neutral
Date Type Details
19 Nov 2026 Yahoo Finance Corcept Therapeutics (CORT) Stock May Look Fully Valued Despite Cancer Case Report
Corcept Therapeutics has seen its share price swing sharply in recent months, which puts a fresh spotlight on a basic question for investors: whether today's valuation is supported by the earnings the business is generating. Over the past 5 years, Corcept Therapeutics has delivered a share price…
18 Nov 2026 Yahoo Finance What Is Driving The Move In Corcept Therapeutics Stock?
Today's big story: Anthropic IPO: Priced For 2031, Or 2036…
16 Nov 2026 Yahoo Finance ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
REDWOOD CITY, Calif., November 16, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone…
06 Nov 2026 Yahoo Finance Can You Justify Buying Corcept Stock Today?
For questions about this article or underlying research, email [email protected].
06 Nov 2026 Yahoo Finance Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
Corcept Therapeutics (CORT) just delivered a sharp jump in profitability in its third quarter report, with net income of US$126.78 million and diluted EPS of US$1.01 from continuing operations. That profit jump landed against a sharp reset in sentiment, with Corcept Therapeutics’ share price down…
04 Nov 2026 Yahoo Finance Corcept Therapeutics Incorporated Q3 2026 Earnings Call Summary
Moby summary of Corcept Therapeutics Incorporated's Q3 2026 earnings call…
04 Nov 2026 Yahoo Finance Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
Corcept Therapeutics Inc (CORT) posted $340.5 million in Q3 2026 revenue on explosive oncology growth, reiterated its full-year guidance, and now awaits a December 17 FDA decision on relacorilant.
04 Nov 2026 Yahoo Finance Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript
Lifyorli's launch and a new metabolic pipeline shaped the quarter.
04 Nov 2026 Yahoo Finance CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
03 Nov 2026 Yahoo Finance Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results. Net income totaled $126.8 million, compare…
03 Nov 2026 Yahoo Finance Corcept Therapeutics falls on guidance despite earnings beat
Investing.com -- Corcept Therapeutics Incorporated (NASDAQ:CORT) reported third-quarter results that exceeded analyst expectations, though shares fell 3.9% in after-hours trading Tuesday as the company's reiterated full-year guidance disappointed investors.
03 Nov 2026 Yahoo Finance Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
03 Nov 2026 Yahoo Finance Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 64% year on year to $340.5 million. The company expects the full year’s revenue to be around $1.15 billion, close to analysts’ consensus estimates. Its GAAP profit…
03 Nov 2026 Yahoo Finance Corcept: Q3 Earnings Snapshot
(AP) — Corcept Therapeutics Inc. (CORT) on Tuesday reported third-quarter earnings of $124…
03 Nov 2026 Yahoo Finance Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., November 03, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone…
27 Oct 2026 Yahoo Finance Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif., October 27, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m.…
26 Oct 2026 Yahoo Finance What Corcept Therapeutics Stock Positive Trial Results Mean For Shareholders
Corcept Therapeutics recently reported Part A results from its Phase 2 BELLA trial. In 95 women with platinum-resistant ovarian cancer, Lifyorli plus nab-paclitaxel and bevacizumab showed longer median PFS and higher ORR than Lifyorli plus nab-paclitaxel and nab-paclitaxel alone in the separate…
26 Oct 2026 Yahoo Finance Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif., October 26, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone…
26 Oct 2026 Yahoo Finance Can Corcept Therapeutics Stock Rally 40% After This Dip?
For questions about this article or underlying research, email [email protected].
23 Oct 2026 Yahoo Finance Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Investing.com -- Shares of Genmab A/S (NASDAQ: GMAB) rallied 9% on Friday following the announcement of positive top-line results from its Phase 3 RAINFOL-02 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. Meanwhile, shares of Corcept Therapeutics…
22 Oct 2026 Yahoo Finance 2 cash-producing stocks to research further and 1 we find risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
20 Oct 2026 Yahoo Finance 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
REDWOOD CITY, Calif., October 20, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone…
19 Oct 2026 Yahoo Finance Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
Show more

Technical Setup Medium

Trend order
Slope
Entry –
Volume
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days.
Nearest support: 57.98 – 60.42 · weak level
Nearest resistance: 69.29 – 72.51 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria